SCHEMBL31307396

SCHEMBL31307396

O=Cc1ccc(OCc2ccccc2)c(OCCNC(=O)OCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
MAPT P10636 1/20 0.52
KDM4E B2RXH2 3/20 0.48
APP P05067 2/20 0.48
ALDH1A1 P00352 1/20 0.47
HTT P42858 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
TACR2 P21452 1/20 0.46
TGM2 P21980 1/20 0.46
HTR1A P08908 1/20 0.45
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45
NPC1 O15118 1/20 0.45
CYP2C9 P11712 1/20 0.45
RAB9A P51151 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23200624 0.90 KDM4E (0.51) LMNASMN1; SMN2MAPTKDM4EAPP
SCHEMBL22425685 0.87 ALDH1A1 (0.48) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL24080293 0.87 ALDH1A1 (0.48) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL18569789 0.84 KDM4E (0.47) LMNASMN1; SMN2MAPTKDM4EAPP
SCHEMBL13904260 0.81 L3MBTL1 (0.56) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL584489 0.81 TACR2 (0.62) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL29446267 0.81 TACR2 (0.62) LMNASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL21738205 0.80 TACR2 (0.53) LMNASMN1; SMN2KDM4EAPPALDH1A1
SCHEMBL28535059 0.80 POLB (0.53) LMNASMN1; SMN2MAPTKDM4EAPP
SCHEMBL5213944 0.79 TACR2 (0.54) LMNASMN1; SMN2MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12173018-B2 Penicillin-binding protein inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2024-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12173018-B2 Penicillin-binding protein inhibitors PEPD, BPGM, EBPL LMNA 3468/4885SMN1; SMN2 3101/4885L3MBTL1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.